Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS
CompanyDrug

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Pharmaceutical Holding Group Co., Ltd. (WEPON) (SHE: 002082) announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding its plan to conduct a…

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised

BMS Q3 Revenue Rises 7% to USD 13.1 Billion as Eliquis Surges 25% and Growth Portfolio Climbs 12%; Full‑Year Outlook Raised

Sino Biopharmaceutical's CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Sino Biopharmaceutical’s CTTQ Partners with Revvity to Launch X‑Lab Joint Shared Laboratory for Antibody Drug R&D

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

BMS Presents Promising Golcadomide Trial Results for Non-Hodgkin Lymphomas

CompanyDrug

J&J’s Carvykti Demonstrates Extended Time to Symptom Worsening in Multiple Myeloma Patients

CompanyDrug

Shanghai Henlius Biotech Submits Another Application for Serplulimab in China

CompanyDrug

HutchMed’s Elunate-Tyvyt Combination Study for Renal Cell Carcinoma Completes Enrollment

CompanyDrug

Luye Pharma’s Lurbinectedin Receives Market Approval in Hong Kong for SCLC Treatment

CompanyDrug

BMS Advances TIGITxCD96 Bispecific Antibody into Phase II Dose Expansion

CompanyDeals

Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate

CompanyDrug

Kelun-Biotech’s SKB264 NDA Accepted by NMPA for mTNBC, Poised to Be China’s First TROP2-targeted ADC

Show More